Evidence strength for the context described on this page.
PEPTIDE ATLAS / METABOLIC & FAT LOSS / TESAMORELIN
EvidenceHigh for approved indicationi
RegulatoryFDA-approvedi
Tesamorelin

Approved for excess abdominal fat in adults with HIV lipodystrophy—not general weight loss.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
The five facts to know first.
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Plus 0 research searches. A search link is not a cited study or proof of a claim.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.
How we describe evidence →OVERVIEW
What Tesamorelin is.
A growth-hormone-releasing factor analog that increases endogenous GH pulsatility and IGF-1. Its approval is narrow and does not establish routine anti-aging or visceral-fat use outside HIV lipodystrophy.
Stimulates pituitary growth-hormone release, raising IGF-1 and changing visceral adipose tissue in the labeled population.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Reduces excess abdominal fat in adults with HIV and lipodystrophy
- Does not replace management of HIV or general cardiometabolic risk
- General obesity treatment
- Longevity enhancement
- Bodybuilding or recovery in healthy adults
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Approval applies to a specific product and indication. A licensed clinician must evaluate whether the exact treatment fits your history, current medications and goals.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- IGF-1
- Glucose status
- Waist/visceral-fat response
- Injection reactions and fluid retention
SAFETY
Risks, red flags and reasons to avoid it.
- Elevated IGF-1
- Glucose intolerance or diabetes
- Fluid retention, joint symptoms and injection-site reactions
- Concern in active malignancy
- Pregnancy
- Active malignancy
- Disrupted hypothalamic-pituitary axis
- Using it as an unsupervised fat-loss peptide
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Prescription-only FDA-approved products for a narrow indication.
Marketing often strips away the HIV-lipodystrophy indication. The approved dose is not a general body-composition protocol.
Learn now. Verify care separately.
This guide is not a booking or prescribing service. Clinical appointments and prescription decisions are handled separately from this educational Atlas.
Review care readiness and standards →NEXT STEP
Return to metabolic & fat loss peptides.
Explore the category →YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools